A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
about
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancerGene expression profiling predicts clinical outcome of prostate cancerThe University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomyRisk stratification and early oncologic outcomes following robotic prostatectomyRisk assessment for prostate cancer metastasis and mortality at the time of diagnosisAssociation of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomyADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerChallenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsCurrent clinical challenges in prostate cancerRationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancerOutcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into accountPre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancerPreoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical ProstatectomyDesign of a Global Medical Database which is Searchable by Human Diagnostic PatternsGenetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.A centralized research data repository enhances retrospective outcomes research capacity: a case reportDecreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancerCarboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer.Prostate cancer-associated gene expression alterations determined from needle biopsies.Molecular sampling of prostate cancer: a dilemma for predicting disease progression.Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.Future prospects in prostate cancer.Clinical risk-stratification for prostate cancer: Where are we, and where do we need to go?Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.Adjuvant medical therapy for prostate cancer.Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.Incremental value of magnetic resonance imaging in the advanced management of prostate cancer.A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer.Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.Artificial neural networks for prostate carcinoma risk assessment: An overview.The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen.Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers
P2860
Q24569630-0F4E2D73-BBD8-4400-A420-0A11DFE34825Q24594253-EFD4E2E2-98FB-4E85-9169-6FEA946B7814Q24596735-9A751252-39E6-4E29-AF7A-62658C30631CQ24632732-8FC7E95B-A872-4961-B3C5-5D03B23547C3Q24645292-F97EE518-D286-485A-A417-62843658226BQ24652928-5AB11C33-25B8-47D4-8D42-95EAFA9977FEQ24676359-CA9E0CEE-9712-4AAE-99A6-464FA45FB9E1Q26773634-EE423443-5A17-44E5-9A66-DB76141D3399Q26773738-BE2F7981-C611-4070-A740-EE9F6690D0A9Q26866036-6BCC4069-7E6D-4D9C-B339-232E4B7C15E0Q27028084-9F05D973-751F-47F4-A710-21AFBA444BD6Q27308897-4D440DF9-9169-4D0D-B7F7-263370D33B4AQ27852185-C9BC6D84-912B-43D1-97B7-903FE55CD7DAQ28079221-7712CC98-3FF7-4489-AC8F-947EF0D200E4Q28484126-3FE87771-A446-4BC8-8940-F21969D27046Q28539777-D0F4288B-A7A3-43DC-91E4-B4669C306F5EQ28552107-BA398CC8-047D-4135-83BF-CC48436CDF42Q28754787-71FD8ECC-B942-496D-93F7-29B8B74856E0Q30504100-72899570-A489-434E-98A8-679CB02D0713Q30586194-D43B800A-8EF1-4A24-95F8-9F6CB4C9B959Q33298583-DD2E5041-C067-4A94-A15B-7B35362A6D69Q33412912-B7E10951-902E-4628-A40D-0F1E8989EFBBQ33430210-FCED0424-68D3-4546-AD57-894BA9EBFEC7Q33541296-9C037EEE-B497-451E-A54F-A4F6BF04A5C7Q33631383-98B61E67-0DEF-4F8C-989C-0E39C859AFC8Q33695955-C40363E7-3FD4-45D1-B8F7-41205566B693Q33696654-03497F07-6BFF-49D8-8057-08D5E6A7B3B4Q33705993-5FBCA01D-0379-46D9-AF7B-AD569D32E0B0Q33758771-6CAFA333-40CD-4434-ADED-DA703C306F34Q33759217-1A8D4B7F-D53B-46C3-A830-935167EB9045Q33772524-80B7B122-7122-44CA-B77C-4F6B790D545FQ33787023-7824B0D7-A8B2-44C0-A9C9-3EE347AEF0CEQ33800997-4B40B4C9-6BEB-431A-A585-67C00839805BQ33880813-079DBE57-76CB-45AA-92C3-F42E0B737171Q33922385-FDF8A512-A7EA-4D59-9286-953623F5BA8FQ33940082-18C30565-7697-40D9-A8DB-636861E5A994Q33952169-161A9C79-9A96-4D44-8D37-2C1529527DA7Q33958709-B24750AA-99BC-4855-BA30-3E217EF168B3Q33965472-7CA34130-C026-4D31-AE31-C6796E2FD303Q34033258-A98E7290-A9A2-497F-8DA0-19D0F9645FE2
P2860
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@en
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@nl
type
label
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@en
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@nl
prefLabel
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@en
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@nl
P2093
P356
P1476
A preoperative nomogram for di ...... tatectomy for prostate cancer.
@en
P2093
Eastham JA
Scardino PT
Stapleton AM
Wheeler TM
P304
P356
10.1093/JNCI/90.10.766
P407
P577
1998-05-01T00:00:00Z